Cross-Sector entity
Kate Rausch is most often covered alongside Activin E, which appears in 2 of these 2 stories. The clearest coverage concentration is clinical-trial: 1 of 2 stories, with the rest divided among 1 other category. Kate Rausch appears in 2 tracked Cross-Sector stories from August 4, 2026.
2 verified stories tracked
Last mentioned: Aug 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Kate Rausch is most often covered alongside Activin E, which appears in 2 of these 2 stories. The clearest coverage concentration is clinical-trial: 1 of 2 stories, with the rest divided among 1 other category. Kate Rausch appears in 2 tracked Cross-Sector stories from August 4, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Kate Rausch. Shared-story counts are live from our verified record — not editorial picks.
Wave Life Sciences presented Phase I data for WVE-007, an siRNA targeting Activin E, demonstrating up to 88% serum reduction sustained for over 7.5 months. The INLIGHT Phase IIa trial is now enrolling 160 patients across four cohorts, with a focus on BMI 35–50 and type 2 diabetes status, aiming to validate the RNA editing platform's potential for durable obesity treatment.
Wave Life Sciences' WVE-007, a novel siRNA silencing Activin E, demonstrated a 16.5% improvement in visceral fat-to-muscle ratio in Phase I, outpacing existing therapies and offering a potential solution for the 70% of GLP-1 users who discontinue within a year. With enrollment underway in the INLIGHT Phase IIa trial, the 175 million individuals with obesity in the U.S. and Europe may soon have a longer-lasting, disease-modifying option.
Source: Motley Fool Transcribing (us) · fool.com
